Clinical Trials Logo

Relapsed and Refractory clinical trials

View clinical trials related to Relapsed and Refractory.

Filter by:
  • None
  • Page 1

NCT ID: NCT04626908 Not yet recruiting - Clinical trials for Relapsed and Refractory

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Start date: November 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

NCT ID: NCT04283006 Recruiting - Clinical trials for Relapsed and Refractory

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Start date: May 23, 2018
Phase: Early Phase 1
Study type: Interventional

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.

NCT ID: NCT03376958 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Start date: January 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.

NCT ID: NCT02282358 Terminated - Lymphoma Clinical Trials

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to learn if the study drug mocetinostat can slow the progression of cancer in people who have a mutation in CREBBP or EP300 in the genetic makeup of their cancer. The potential side effects of mocetinostat will also be studied.